Answers are grounded in this paper and cite their sources.
This study aims to explore how the abused synthetic cannabinoids in human urine can be determined qualitatively and quantitatively by using the LC-MS/MS method. As a method validation based on the current FDA guideline, we tested 55 human urine samples (5 from drug-free volunteers and 50 from drug abusers) and evaluated the presence of parent drugs (UR144 and XLR11) and their five metabolites (XLR-11-N-4-Hydroxypentyl, XLR-11-6-Hydroxyindole, UR-144-N-4-Hydroxypentyl, UR-144-N-5-hydroxypentyl, and UR-144-N-pentanoic). The experimental data showed that the values of low limit of detection (LOD) for these analytes ranged from 0.05 to 0.15 ng/mL. Their low limit of quantitation (LLOQ) value was 1.0 ng/mL. The values of linear coefficients of determination (R2) for these analytes ranged from 0.9914 to 0.9988. Among these 50 urine testing samples of drug abusers, the parent XLR-11 and UR-144 analytes were detected only in 4 samples (with a concentration of 2.14 − 4.5 ng/mL) and 3 samples (with a concentration of 3.2 − 5.4 ng/mL), respectively. At the same time, the XLR-11-N-4-Hydroxypentyl (with a concentration of 4.5 − 57.2 ng/mL) and XLR-11-6-Hydroxyindole (with a concentration of 4.8 − 51.7 ng/mL) metabolites were detected in 24 and 11 samples, respectively. In addition, the UR-144-N-4-Hydroxypentyl (with a concentration of 3.5 − 87.24 ng/mL), UR-144-N-5-hydroxypentyl (with a concentration of 14.5-83.9 ng/mL), and UR-144-N-pentanoic (with a concentration of 2.5 − 104.4 ng/mL) metabolites were found in 26, 29, and 38 samples, respectively.
No takes yet. Share an insight, caveat, or question.
Dang et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: